LOX and LOXL2 inhibitors and uses thereof
First Claim
1. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to a lysyl oxidase-like 2 (LOXL2) protein and comprises a heavy chain variable region comprising complementarity determining region (CDR)1, CDR2 and CDR3 comprising the amino acid sequences set forth as SEQ ID NOs:
- 41, 42, and 70, respectively, and a light chain variable region comprising CDR1, CDR2 and CDR3 comprising the amino acid sequences set forth as SEQ ID NOs;
57, 58, and 59, respectively.
2 Assignments
0 Petitions
Accused Products
Abstract
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
-
Citations
22 Claims
-
1. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to a lysyl oxidase-like 2 (LOXL2) protein and comprises a heavy chain variable region comprising complementarity determining region (CDR)1, CDR2 and CDR3 comprising the amino acid sequences set forth as SEQ ID NOs:
- 41, 42, and 70, respectively, and a light chain variable region comprising CDR1, CDR2 and CDR3 comprising the amino acid sequences set forth as SEQ ID NOs;
57, 58, and 59, respectively. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)
- 41, 42, and 70, respectively, and a light chain variable region comprising CDR1, CDR2 and CDR3 comprising the amino acid sequences set forth as SEQ ID NOs;
Specification